Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Globe Newswire•17/08/2026•17:33 ET
0
Whiz Insights
– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –
– Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company –
Get started
Create a free account to read the full story.